TRAnsFORM: Trial Assessments of Fitness and Outcomes Research in Myeloma

TRansFORM：骨髓瘤健康和结果研究的试验评估

• 批准号: MR/W030128/1
• 负责人: Christopher Parrish
• 金额: $ 25.35万
• 依托单位: University of Leeds
• 依托单位国家: 英国
• 项目类别: Research Grant
• 财政年份: 2022
• 资助国家: 英国
• 起止时间: 2022 至 无数据
• 项目状态: 未结题
• 来源: https://gtr.ukri.org/projects?ref=MR%2FW030128%2F1
• 关键词: TRAnsFORM; Trial; Assessments; Fitness; Outcomes

BackgroundOur population is ageing, and as this happens the rates of cancer are increasing. However, as people age the risk of other diseases also increases, for example heart disease, stroke, diabetes, joint disease and many others, leading to frailty. To provide cancer treatment safely and effectively to older people we therefore need to adjust the therapies we use according to an individual's level of fitness, so that more patients can receive treatment and side effects can be reduced. Unfortunately at present we do not have reliable ways of measuring frailty or judging which therapies are likely to be best for which people. This research tests an entirely new approach to calculating an individual's frailty.AimsThis project will test whether wearable activity trackers, similar to those often used for sports and exercise, can measure activity levels in older adults undergoing cancer treatment, and whether the information from the trackers can help patients and their doctors make better choices about which therapies are most suitable for them.Research PlanWe will approach patients who have already agreed to take part in a large clinical study that is testing treatments for older adults with multiple myeloma (a common blood cancer). Patients who take part in our project will wear a tracker before and during their cancer treatment, for about 3 months. We will analyse the data collected and combine this with data collected from the larger clinical study such as how well treatments work and side effects that occur.Benefits of the ResearchWe will use the information from the trackers to develop better ways of testing frailty; these could help doctors to personalise the treatments offered to elderly or frail patients in the future. One benefit will be identifying patients who are older but actually very fit and who could benefit from standard treatment. Equally importantly, we will be able to ensure that those for whom standard doses are likely to cause multiple side effects can be offered gentler therapies that would work better. We're starting this research in people with multiple myeloma, however it's likely the tools we develop could help people with other cancers and chronic diseases. We will make sure the results of the research are released quickly and widely so the maximum number of patients can benefit.About the ResearcherI am a Consultant Haematologist working in Leeds. I spend most of my time caring for people with multiple myeloma, many of whom are elderly. I am passionate about making sure that elderly and frail people get the best possible treatments for their cancers, and I have a superb team of researchers working with me to ensure this project is successful.

背景我们的人口正在老龄化，随着这种情况的发生，癌症的发病率也在增加。然而，随着人们年龄的增长，其他疾病的风险也会增加，例如心脏病，中风，糖尿病，关节疾病和许多其他疾病，导致虚弱。因此，为了安全有效地为老年人提供癌症治疗，我们需要根据个人的健康水平调整我们使用的治疗方法，以便更多的患者可以接受治疗，并减少副作用。不幸的是，目前我们还没有可靠的方法来衡量脆弱性或判断哪种疗法可能对哪些人最好。这项研究测试了一种全新的方法来计算一个人的脆弱性。目的这个项目将测试可穿戴活动跟踪器，类似于那些经常用于运动和锻炼，可以测量活动水平在老年人接受癌症治疗，以及来自追踪器的信息是否可以帮助患者和他们的医生更好地选择最适合他们的治疗方法。研究计划他们已经同意参加一项大型临床研究，该研究正在测试对患有多发性骨髓瘤（一种常见的血癌）的老年人的治疗。参加我们项目的患者将在癌症治疗前和治疗期间佩戴追踪器，为期约3个月。我们将分析收集到的数据，并将其与更大规模的临床研究中收集到的数据（如治疗效果如何以及发生的副作用）联合收割机结合起来。研究的好处我们将利用跟踪器提供的信息开发更好的虚弱测试方法;这些方法可以帮助医生在未来为老年人或虚弱患者提供个性化的治疗。其中一个好处是确定年龄较大但实际上非常健康的患者，他们可以从标准治疗中受益。同样重要的是，我们将能够确保那些标准剂量可能导致多种副作用的人可以得到更温和的治疗，效果更好。我们正在多发性骨髓瘤患者中开始这项研究，但我们开发的工具很可能可以帮助患有其他癌症和慢性疾病的人。我们将确保研究结果迅速广泛地发布，以便最大数量的患者能够受益。关于研究人员我是一名在利兹工作的顾问血液学家。我大部分时间都在照顾多发性骨髓瘤患者，其中许多人是老年人。我热衷于确保老年人和体弱者获得最好的癌症治疗，我有一个优秀的研究团队与我合作，以确保这个项目的成功。